AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B – PR Newswire

  1. AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B  PR Newswire
  2. AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B  Eastern Progress
  3. AusperBio Secures $63 Million in Series B2 Funding to Advance Chronic Hepatitis B Therapies  geneonline.com

Continue Reading